Endometrial cancer is a widely recognized female threat. It usually affects around 40,000 women every year. Numerous prospective arbitrary trials have been published. However, despite that, there still happens to be a lot of debate regarding the utilization of adjuvant radiation therapy in the management of endometrial cancer. It is perspicuous that most women who have been diagnosed with early-stage and low-risk cancer will be fine without getting adjuvant radiotherapy. There is a danger of local-regional relapse for intermediate-risk patients. Radiation therapy had been found to efficaciously decrease this risk without crucially affecting the overall survival of the patient. The lack of a distinct influence on survival led to a shortfall of agreement in regards to the utilization of radiotherapy in patients with intermediate-risk. Simultaneously, there were a variety of suggestions regarding suitable radiotherapy targets due to the patterns of failures in patients with intermediate-risk. Both local and distant failures are dangerous for high-risk patients. Chemotherapy, however, was found to make the results better in patients with such cases. Targeted radiotherapy might be a suitable option for patients with high risk who were exposed to the dangers of local failure.